AMNEAL PHARMACEUTICALS, INC. Unusual or Infrequent Item, or Both, Net of Insurance Proceeds
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Unusual or Infrequent Item, or Both, Net of Insurance Proceeds of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Notes › Unusual or Infrequent Item, or Both, Net of Insurance Proceeds
us-gaap:UnusualOrInfrequentItemNetOfInsuranceProceeds · last filed 2024-03-14
- AMNEAL PHARMACEUTICALS, INC. unusual or infrequent item, or both, net of insurance proceeds for the quarter ending 2022-12-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. unusual or infrequent item, or both, net of insurance proceeds for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. unusual or infrequent item, or both, net of insurance proceeds for the quarter ending 2021-12-31 was -$2.82M.
- AMNEAL PHARMACEUTICALS, INC. unusual or infrequent item, or both, net of insurance proceeds for the quarter ending 2021-09-30 was $8.19M.
- AMNEAL PHARMACEUTICALS, INC. unusual or infrequent item, or both, net of insurance proceeds for fiscal 2023 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. unusual or infrequent item, or both, net of insurance proceeds for fiscal 2022 was -$1.91M, a 135.60% decline from fiscal 2021.
- AMNEAL PHARMACEUTICALS, INC. unusual or infrequent item, or both, net of insurance proceeds for fiscal 2021 was $5.37M.
| Period end | Unusual or Infrequent Item, or Both, Net of Insurance Proceeds 3 month | Unusual or Infrequent Item, or Both, Net of Insurance Proceeds 6 month | Unusual or Infrequent Item, or Both, Net of Insurance Proceeds 9 month | Unusual or Infrequent Item, or Both, Net of Insurance Proceeds 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | -$1.91M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-07 | -$1.91M 10-Q · filed 2022-11-07 | ||
| 2021-12-31 | -$2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $5.37M derived: sum of 2 quarters · filed 2024-03-14 | $5.37M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $8.19M 10-Q · filed 2022-11-07 | $8.19M 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |